ICAD, Inc. Provides Revenue Guidance for the Fourth Quarter of 2021 and for the Full Year 2021
January 04, 2022 at 08:00 am EST
Share
iCAD, Inc. provided revenue guidance for the fourth quarter of 2021 and for the full year 2021. Based on preliminary, unaudited financial information, the Company expects total revenue for the fourth quarter of 2021 to be between $7.8 and $8.0 million.
The total revenue for the full year 2021 to be approximately $33.6 to $33.8 million.
iCAD, Inc. is a global medical technology company, which provides cancer detection and therapy solutions. The Company is focused on providing breast cancer detection solutions built on artificial intelligence (AI) that empowers radiologists to find cancers. Its solutions include advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier, and a range of high-performance, AI and computer-aided detection (CAD) systems and workflow solutions for 2D and 3D mammography, magnetic resonance imaging and computed tomography (CT). The Companyâs Breast AI Suite offers a triple threat of clinically proven cancer detection, density assessment, and risk evaluation solutions, designed to accelerate discovery and improve outcomes. It also offers ProFound AI, a digital breast tomosynthesis (DBT) cancer detection and workflow solution.
ICAD, INC. 
